Merck KGaA
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kai Beckmann
- Full Time Employees
- 62,461
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Frankfurter Strasse 250 Darmstadt HE Germany 64293
- IPO Date
- Aug 3, 2012
- Website
- merckgroup.com
- Similar Companies
- Business
- Merck KGaA, headquartered in Darmstadt, Germany, and founded in 1668, operates as a leading science and technology company with three core business sectors: Healthcare; Life Science; and Electronics; serving customers in over 65 countries across Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa. In Healthcare, the company discovers, develops, manufactures, and markets prescription pharmaceuticals and biopharmaceuticals focused on oncology (including Erbitux and Bavencio), neurology and immunology (such as Rebif and Mavenclad for multiple sclerosis), fertility (featuring Gonal-f), and cardiology, metabolism, and endocrinology; in Life Science, it provides science and lab solutions (reagents, consumables, instruments, and services under brands like Sigma-Aldrich, MilliporeSigma, Milli-Q, and Bioreliance), process solutions (filtration, chromatography, single-use systems for biopharma manufacturing), and life science services (including CDMO and contract testing for biotech, pharma, diagnostics, academia, and industrial clients); in Electronics, it supplies semiconductor solutions, display solutions (liquid crystals), and surface solutions (effect pigments, cosmetics, and functional materials for automotive, consumer electronics, and industrial applications). Recent major developments include the completion of its $3.4 billion acquisition of SpringWorks Therapeutics in July 2025 to bolster its oncology pipeline with rare tumor therapies like Ogsiveo (niacestant) and mirdametinib; a September 2025 memorandum of understanding with Siemens to extend their partnership for AI-driven drug discovery, development, and manufacturing using Dotmatics technology; a €70 million investment announced in October 2024 to expand antibody-drug conjugate (ADC) manufacturing capacity in St. Louis, Missouri; and a $1.4 billion multi-year collaboration with Caris Life Sciences in April 2025 for tumor target identification to advance its internal ADC candidate M9140.
Company News
363,066 Shares in Merck KGaA $MKGAF Purchased by Beacon Pointe Advisors LLC
Blue Edge Capital LLC Decreases Stake in Merck KGaA $MKGAF
Bamco Inc. NY Buys Shares of 22,000 Merck KGaA $MKGAF
ADAR1 Capital Management LLC Invests $403,000 in Merck KGaA $MKGAF
Ancora Advisors LLC Invests $2.69 Million in Merck KGaA $MKGAF
Ausdal Financial Partners Inc. Takes Position in Merck KGaA $MKGAF
AFT Forsyth & Company Inc. Invests $822,000 in Merck KGaA $MKGAF
7,331,418 Shares in Merck KGaA $MKGAF Purchased by Barrow Hanley Mewhinney & Strauss LLC
Barbara Oil Co. Makes New Investment in Merck KGaA $MKGAF
Ally Financial Inc. Takes $4.50 Million Position in Merck KGaA $MKGAF
Emerald Investment Advisers LLC Makes New Investment in Merck KGaA $MKGAF
B. Metzler seel. Sohn & Co. AG Takes Position in Merck KGaA $MKGAF
Bell & Brown Wealth Advisors LLC Invests $5.66 Million in Merck KGaA $MKGAF
August Group Capital Ltd Takes Position in Merck KGaA $MKGAF
9,092 Shares in Merck KGaA $MKGAF Acquired by Asahi Life Asset Management CO. LTD.
BOK Financial Private Wealth Inc. Acquires Shares of 4,043 Merck KGaA $MKGAF
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Up – Should You Buy?
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade